Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children
Status:
Completed
Trial end date:
2020-08-26
Target enrollment:
Participant gender:
Summary
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are widely used as part of
combination antiretroviral therapy (ART) for infants and children, but NNRTI resistance is
increasing, leading to treatment failure. This study tested the safety, tolerability, and
dosing levels of etravirine (ETR), a new NNRTI.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)